Mikhail Dvorkin

11.2k citations

43 papers · 924 indexed · 1 hit paper · h-index 13

Oncology top 5%
- Lung Cancer Research Studies 13
- HER2/EGFR in Cancer Research 9
- Colorectal Cancer Treatments and Studies 6
- Cancer Immunotherapy and Biomarkers 6
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 10
Cancer Research top 10%
- Cancer Genomics and Diagnostics 8
Immunology
- Biosimilars and Bioanalytical Methods 9
Otorhinolaryngology top 10%
Molecular Biology
- Cancer therapeutics and mechanisms 6

Co-authors: Igor Bondarenko Yaroslav Shparyk Ekaterina Trishkina Alexey Manikhas Matthew J. Ellis Shinzaburo Noguchi Servando Cardona‐Huerta Lynda Grinsted
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: The Lancet (1 paper)Journal of Clinical Oncology (15 papers)SHILAP Revista de lepidopterología (1 paper)
Partner nations: United States Russia Italy

In The Last Decade

Mikhail Dvorkin

42 papers receiving 906 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mikhail Dvorkin

Since Specialization

Citations

This map shows the geographic impact of Mikhail Dvorkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Dvorkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Dvorkin more than expected).

Fields of papers citing papers by Mikhail Dvorkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikhail Dvorkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Dvorkin. The network helps show where Mikhail Dvorkin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mikhail Dvorkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mikhail Dvorkin Line = papers co-authored together Mikhail Dvorkin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3 Cancer ·Tamta Makharadze,Ruben G.W. Quek,Tamar Melkadze,Miranda Gogishvili,Cristina Ivanescu,Davit Giorgadze,Mikhail Dvorkin,Konstantin Penkov,К. К. Лактионов,Gia Nemsadze,Marina Nechaeva,Irina Rozhkova,Ewa Kalinka‐Warzocha,Christian Geßner,Brizio Moreno‐Jaime,Rodolfo Passalacqua,Gerasimos Konidaris,Petra Rietschel,Giuseppe Gullo	2023	8
2	Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results Cancer Medicine ·Fortunato Ciardiello,Yung‐Jue Bang,Andrés Cervantes,Mikhail Dvorkin,Charles D. Lopez,Jean‐Philippe Metges,Antonio Sánchez Ruiz,Mariona Calvo,Andrew Strickland,George Kannourakis,Kei Muro,Hisato Kawakami,Wei Jia,Christophe Borg,Zhaoyin Zhu,Neal Gupta,Robert J. Pelham,Lin Shen	2023	6
3	Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study SHILAP Revista de lepidopterología ·Shalu Kasliwal,K. Ranjith,Pramod Reddy,Narendra Maharaj,Gopichand Mamillapalli,Aditya Adhav,Kamlesh Kumar Harsh,Nagesh Madnoorkar,Ashok Kumar Diwan,Mamraj Gupta,Ghanshyam Patel,B. J. Srinivas,Mikhail Dvorkin	2023	2
4	Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study) Medical alphabet ·А. В. Султанбаев,R. I. Fatyhov,O. A. Gladkov,Mikhail Dvorkin,E. P. Solovieva,Sergey Cheporov,Alexey Loleit,E. I. Ruzavina	2023	0
5	LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial Annals of Oncology ·Mustafa Özgüroğlu,Saadettin Kılıçkap,A. Sezer,(unknown),Igor Bondarenko,M. Gogishvili,Marina Nechaeva,M. Schenker,(unknown),Gwo Fuang Ho,Y. Kulyaba,Mikhail Dvorkin,K. Zyuhal,R.I. Scheusan,S. Li,J-F. Pouliot,Frank Seebach,I. Lowy,G. Gullo,Petra Rietschel	2022	7
6	1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study Annals of Oncology ·Chuanlong Zhou,Dongmei Huang,Yong Fan,Xiaodong Yu,Yihan Li,Yongqian Shu,Zhe Ma,Z. Wang,Yin Cheng,J. Wang,Sheng Hu,E. Poddubskaya,Umut Dişel,A. Akopov,Mikhail Dvorkin,Y. Wang,S. Ghassemifar,S. Li,Gareth Rivalland	2022	1
7	Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. Journal of Clinical Oncology ·Ying Cheng,Liang Han,Lin Wu,Jun Chen,Hongmei Sun,Guilan Wen,Yinghua Ji,Mikhail Dvorkin,Jianhua Shi,Zhijie Pan,Jinsheng Shi,Xicheng Wang,Yuansong Bai,Tamar Melkadze,Yueyin Pan,Xuhong Min,Maksym Viguro,Yan Xu,Qingyu Wang,Jun Zhu,(unknown)	2022	22
8	93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial Annals of Oncology ·Tamta Makharadze,Ruben G.W. Quek,Tamar Melkadze,Miranda Gogishvili,Cristina Ivanescu,D. Giorgadze,Mikhail Dvorkin,Konstantin Penkov,К. К. Лактионов,Gia Nemsadze,M. Nechaeva,I. Rozhkova,Ewa Kalinka‐Warzocha,Christian Geßner,Brizio Moreno‐Jaime,Rodolfo Passalacqua,Gerasimos Konidaris,Petra Rietschel,Giuseppe Gullo	2021	1
9	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study Gastric Cancer ·Wasat Mansoor,Hendrik‐Tobias Arkenau,María Alsina,Kohei Shitara,Peter Thuss‐Patience,Sinéad Cuffe,Mikhail Dvorkin,Jae‐Hyun Park,Takayuki Ando,Marc Van den Eynde,Giordano Beretta,Alberto Zaniboni,Toshihiko Doi,Josep Tabernero,David H. Ilson,Lukas Makris,Karim A. Benhadji,Eric Van Cutsem	2021	6
10	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) BioDrugs ·Konstantinos Syrigos,Istvan Abert,Zoran Andric,Igor Bondarenko,Mikhail Dvorkin,Kristina Galić,Rinat Galiulin,Vladimer Kuchava,Virote Sriuranpong,Dmytro Trukhin,Edvard Zhavrid,Dongyue Fu,Laurent Kassalow,Stephanie Jones,Zahid Bashir,(unknown)	2021	12
11	910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) Annals of Oncology ·Ezra E.W. Cohen,Robert L. Ferris,Amanda Psyrri,Robert I. Haddad,Makoto Tahara,Jean Bourhis,Kevin J. Harrington,P.M-H. Chang,JC Lin,M. Razaq,Margarida Teixeira,József Lövey,J. Chamois,(unknown),Chaosu Hu,Mikhail Dvorkin,Steven De Beukelaer,Dmitri Pavlov,Holger Thurm,N. Lee	2020	30
12	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). Journal of Clinical Oncology ·Markus Moehler,Mikhail Dvorkin,Mustafa Özgüroğlu,Min‐Hee Ryu,Alina Muntean,Sara Lonardi,Marina Nechaeva,Arinilda Silva Campos Bragagnoli,Hasan Şenol Çoşkun,Antonio Cubillo Gracián,Toshimi Takano,Rachel Wong,Howard Safran,Gina M. Vaccaro,Narikazu Boku,Ilaria Conti,Janet Hong,Huiling Xiong,Julien Taı̈eb,Yung‐Jue Bang	2020	36
13	EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment Annals of Oncology ·Meng Su,L. Chen,Erika Hitre,W. Lee,Li‐Yuan Bai,Zsuzsanna Pápai,Seok Yun Kang,Mikhail Dvorkin,Min‐Hsien Lee,ETHEL LUDOVIC,Hong Jun Choi,Sung-Tae Oh,G. Bodoky,Pascal Artru,Jun‐Eul Hwang,I. Bazin,(unknown),Jean‐Baptiste Bachet,Zsolt Horváth,Chirn‐Bin Chang,Johnson Lin	2019	4
14	TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer Annals of Oncology ·Hendrik‐Tobias Arkenau,Josep Tabernero,Kohei Shitara,Mikhail Dvorkin,Was Mansoor,Aliaksandr Prokharau,María Alsina,Michele Ghidini,C. Faustino,В. А. Горбунова,Э. А. Жаврид,Kazuhiro Nishikawa,A. Hosokawa,Doina Ganea,Şuayib Yalçın,Giordano Beretta,R.E. Winkler,Lukas Makris,Toshihiko Doi,D.H. Ilson	2018	1
15	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results European Journal of Cancer ·Xavier Pivot,Igor Bondarenko,Zbigniew Nowecki,Mikhail Dvorkin,Ekaterina Trishkina,Jin‐Hee Ahn,Seock‐Ah Im,Tomasz Sarosiek,Sanjoy Chatterjee,Marek Z. Wojtukiewicz,Yaroslav Shparyk,Vladimir Moiseyenko,Maximino Bello,Semiglazov Vf,Young Jin Lee,Ji Hyoun Lim	2018	53
16	One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment Annals of Oncology ·Xavier Pivot,Igor Bondarenko,Zbigniew Nowecki,Mikhail Dvorkin,Ekaterina Trishkina,Jin‐Hee Ahn,Y. Vinnyk,S-A. Im,Tomasz Sarosiek,Sanjoy Chatterjee,Marek Z. Wojtukiewicz,Vladimir Moiseyenko,Yaroslav Shparyk,Maximino Bello,Semiglazov Vf,L. Younju,Joshua Sheng Hao Lim	2017	6
17	Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) Annals of Oncology ·Josep Tabernero,Fortunato Ciardiello,Clara Montagut,Chunming Ding,Scott Kopetz,Thomas T. Poulsen,Alberto Bardelli,Lucjan Wyrwicz,Antonio Cubillo,Cristina Santos,Guglielmo Fumi,Vittorina Zagonel,Jaafar Bennouna,Salvatore Siena,Alfredo Falcone,Marta Benavent,G. Argiles,Michael Kragh,Ivan D. Horak,Mikhail Dvorkin	2017	2
18	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer. Journal of Clinical Oncology ·Xavier Pivot,Igor Bondarenko,Mikhail Dvorkin,Ekaterina Trishkina,Jin‐Hee Ahn,Seock‐Ah Im,Tomasz Sarosiek,S. Chattopadhyay,Marek Z. Wojtukiewicz,Vladimir Moiseyenko,Yaroslav Shparyk,Maximino Bello,Semiglazov Vf,Sujeong Song,Jae Yun Lim	2017	14
19	FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer Annals of Oncology ·Matthew J. Ellis,Igor Bondarenko,Ekaterina Trishkina,Mikhail Dvorkin,Lawrence Panasci,Alexey Manikhas,Yaroslav Shparyk,Servando Cardona‐Huerta,Kwok‐Leung Cheung,Manuel Jesus Philco-Salas,Manuel Ruíz‐Borrego,Zhi‐Ming Shao,Shinzaburo Noguchi,Lynda Grinsted,M.A. Fazal,Melissa K. Stuart,J. F. R. Robertson	2016	10
20	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialbreakdown → The Lancet ·J.F.R. Robertson,Igor Bondarenko,Ekaterina Trishkina,Mikhail Dvorkin,Lawrence Panasci,Alexey Manikhas,Yaroslav Shparyk,Servando Cardona‐Huerta,Kwok‐Leung Cheung,Manuel Jesus Philco-Salas,Manuel Ruíz‐Borrego,Zhimin Shao,Shinzaburo Noguchi,Jacqui Rowbottom,Mary Stuart,Lynda Grinsted,Mehdi Fazal,Matthew J. Ellis	2016	384

About Mikhail Dvorkin

Mikhail Dvorkin is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 43 papers that have together received 924 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers), Biosimilars and Bioanalytical Methods (9 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer therapeutics and mechanisms (6 papers). The work is most often cited by research in Oncology (746 citations), Pulmonary and Respiratory Medicine (487 citations) and Cancer Research (211 citations). Mikhail Dvorkin has collaborated with scholars based in United States, Russia and Italy. Frequent co-authors include Igor Bondarenko, Yaroslav Shparyk, Ekaterina Trishkina, Alexey Manikhas, Matthew J. Ellis, Shinzaburo Noguchi, Servando Cardona‐Huerta, Lynda Grinsted, Kwok‐Leung Cheung and Lawrence Panasci. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact